Amylyx Pharmaceuticals logo

Amylyx PharmaceuticalsNASDAQ: AMLX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 January 2022

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$361.25 M
-86%vs. 3y high
61%vs. sector
-vs. 3y high
-vs. sector
-89%vs. 3y high
54%vs. sector
-99%vs. 3y high
36%vs. sector

Price

after hours | 7 min ago
$5.27+$0.11(+2.13%)

Dividend

No data over the past 3 years
$416.00 K-$72.70 M

Analysts recommendations

Institutional Ownership

AMLX Latest News

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript
seekingalpha.com09 November 2024 Sentiment: POSITIVE

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2024 Earnings Call Transcript November 7, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Camille Bedrosian - Chief Medical Officer James Frates - Chief Financial Officer Joshua Cohen - Co-Chief Executive Officer Conference Call Participants Charlie Yang - Bank of America Merrill Lynch Michael DiFiore - Evercore ISI Graig Suvannavejh - Mizuho Securities USA Basma Radwan - Leerink Partners Ananda Ghosh - H.C. Wainwright & Co. Joel Beatty - Robert W.

Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
fool.com18 October 2024 Sentiment: POSITIVE

The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
prnewswire.com03 October 2024 Sentiment: NEGATIVE

NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Amylyx insiders caused the company to misrepresent or fail to disclose that (i) RELYVRIO's commercial prospects were overstated; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, RELYVRIO's prescription rate was also overstated; (v) insiders attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO's prescription data; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
globenewswire.com16 September 2024 Sentiment: NEGATIVE

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
businesswire.com28 August 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person in New York City: Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Thursday, September 5, 2024, at 1:50pm ET Baird 2024 Global Healthcare Conference: Fireside chat on Tuesday, September 10, 2024, at 3:45pm ET H.C. Wainwright 26th Annu.

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
prnewswire.com18 July 2024 Sentiment: NEGATIVE

NEW YORK , July 18, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Amylyx insiders caused the company to misrepresent or fail to disclose that (i) RELYVRIO's commercial prospects were overstated; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, RELYVRIO's prescription rate was also overstated; (v) insiders attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO's prescription data; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript
seekingalpha.com10 July 2024 Sentiment: POSITIVE

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Avexitide Acquisition Conference Call July 10, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Joshua Cohen - Co-Chief Executive Officer Camille Bedrosian - Chief Medical Officer James Frates - Chief Financial Officer Conference Call Participants Corinne Jenkins - Goldman Sachs Michael DiFiore - Evercore ISI Graig Suvannavejh - Mizuho Securities Charlie Yang - Bank of America Merrill Lynch Joel Beatty - Robert W. Baird & Company Ananda Ghosh - H.C.

This cheap biotech offers investors a play on ALS if trial data continues to impress
marketwatch.com02 July 2024 Sentiment: POSITIVE

NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.

Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
reuters.com21 June 2024 Sentiment: POSITIVE

Amylyx Pharmaceuticals has agreed to buy the rights to bankrupt drugmaker Eiger BioPharmaceuticals' experimental drug for low blood sugar in a $35.1 million deal, Eiger said in a filing on Friday.

Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
Zacks Investment Research04 April 2024 Sentiment: NEGATIVE

Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%.

  • 1(current)
  • 2
  • 3

What type of business is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

What sector is Amylyx Pharmaceuticals in?

Amylyx Pharmaceuticals is in the Healthcare sector

What industry is Amylyx Pharmaceuticals in?

Amylyx Pharmaceuticals is in the Biotechnology industry

What country is Amylyx Pharmaceuticals from?

Amylyx Pharmaceuticals is headquartered in United States

When did Amylyx Pharmaceuticals go public?

Amylyx Pharmaceuticals initial public offering (IPO) was on 07 January 2022

What is Amylyx Pharmaceuticals website?

https://amylyx.com

Is Amylyx Pharmaceuticals in the S&P 500?

No, Amylyx Pharmaceuticals is not included in the S&P 500 index

Is Amylyx Pharmaceuticals in the NASDAQ 100?

No, Amylyx Pharmaceuticals is not included in the NASDAQ 100 index

Is Amylyx Pharmaceuticals in the Dow Jones?

No, Amylyx Pharmaceuticals is not included in the Dow Jones index

When was Amylyx Pharmaceuticals the previous earnings report?

No data

When does Amylyx Pharmaceuticals earnings report?

The next expected earnings date for Amylyx Pharmaceuticals is 21 February 2025